Circulating tumour DNA guided Adaptive BRAF and MEK Inhibitor therapy (DyNAMIc)

Research summary

Resistance to standard of care treatment for stage III unresectable or stage IV melanoma can develop after about 12-15 months. During this period,the treatment will kill the less resistant cells,meaning a tumour has a greater proportion of cells that are resistant to treatment. This study aims to investigate if the patient having breaks in their treatment,guided by the ctDNA TAB level,allows the less resistant cells to continue to grow,resulting in a tumour with a lower proportion of resistant cells,making the tumour as a whole becoming less resistant to treatment,thus increasing the time it takes to progress. 40 patients will be randomised to receive encorafenib plus binimetinib continuously as per standard of care (Arm A (control),n=10),or encorafenib plus binimetinib for 28 days followed by adaptive (i.e. stop/start) treatment as indicated by ctDNA TAB levels (Arm B (experimental),n=30).

Principal Investigator

Dr Miranda Payne

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1004759